Bing Yao, ArriVent Biopharma CEO
January 22, 2024 07:28 AM ESTUpdated 09:57 AM
Financing
Startups
China

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Kyle LaHucik

Senior Reporter

Ar­riVent Bio­phar­ma, a Penn­syl­va­nia drug­mak­er de­vel­op­ing a Chi­na-ap­proved can­cer treat­ment for the US and oth­er ge­o­gra­phies, plans to raise net pro­ceeds of about $135 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times